.png){kind=logo}
- Insights
- Cryptocurrencies
- Stocks
- White Papers
- Industry
- Geography
- Insights
- Cryptocurrencies
- Stocks
- White Papers
- Industry
- Geography
NIRAMAI Health Analytix is a health technology startup developing a novel solution to detect early-stage breast cancer in a completely privacy-aware manner.
The company's offerings include a cancer diagnosis solution to Hospitals and Diagnostic centers, as well as a low-cost cancer screening solution to improve rural healthcare through Government and Non-Profit Organizations.
Niramai has developed a new technique called Thermalytix™, a novel computer-aided diagnosis solution to identify cancer and pre-cancerous patients in an affordable, accessible and effective way. The solution is a non-contact, non-invasive, low-cost, and portable for detecting breast cancer for women of all ages. The tool does not require expert skills to operate the system and can enable large-scale rural screening. The core of Niramai software consists of novel computer algorithms based on artificial intelligence and machine learning over thermal images.
The key distinctive features of Niramai solutions are:
• Detects cancer long before a lump is felt.
• No radiation, non-contact, non-invasive, privacy-aware technique.
• Works for women of all ages, and works for men too.
• Affordable, portable, light, small screening device enables large-scale rural screening.
The company was incorporated in 2016. Over the last two years, the team has focused on protecting IP, launching the product, establishing clinical validity and establishing centers across three states in India.
Niramai was founded in July 2016 by two women Co-founders, Dr. Geetha Manjunath and Nidhi Mathur with diverse expertise. Geetha, who is the CEO and CTO of the company, holds a Ph.D. in Artificial Intelligence from Indian Institute of Science (IISc) and has led large teams to deliver innovative solutions in Hewlett Packard Labs and Xerox Research. She has over 25 years of research expertise in the IT industry and has several patents, publications, national and international recognitions to her credit. Nidhi holds an MBA from Indian Institute of Management Bangalore (IIMB) with specialization in finance and marketing and has expertise in commercializing new-to-the-world innovations. Nidhi plays the role of COO and CFO at Niramai.
The core mathematics used by Artificial Intelligence (AI) algorithms has now matured and the accuracy levels of automated decision-making have reached the threshold of acceptance, and in some cases even surpassed human decision-making. This has unleashed a new era of innovation creating a real-life impact. AI/Deep Learning Technologies are definitely useful in a country like India where there is a shortage of skilled medical professionals. Niramai makes cancer diagnosis objective, simpler and effective for Radiologists by helping them make more reliable clinical decisions with the help of technology.
Niramai is one of the only four Indian startups invited to participate in the Google Launchpad Accelerator program, one in four selected by Philips for their first edition of HealthWorks program in India, and winner of Amazon AI Award in Healthcare category. The company also won BNP Paribas award for Best Startup in Preventive Healthcare, and Best Startup in Indian Cancer Congress. Niramai also won the BIRAC WinEr 2018 as well as Aegis Graham Bell Award for Data Science category.
The biggest challenge was to prove the clinical validity in an indisputable manner. The company has worked with major hospitals and key experts in the field to establish the efficacy of the solution.
Niramai is working towards increasing the awareness about the solution among women population as well as practitioners. It is partnering with leading medical specialists to create additional proofs of the efficacy of the solution and establish the complete workflow to recommend how this solution can be an integral part of health services delivery. With efforts like that, the company will gradually move the solution towards being the standard modality accepted by a wider section of the medical community. In addition, Niramai is also looking at extending the application of the innovation to areas other than breast cancer.
